Target intelligence / Profile preview

SH3GL interacting endocytic adaptor 1 (SGIP1)

Target
SGIP1
Molecular classification
Endocytic adaptor protein, Clathrin-mediated endocytosis regulator, Muniscin protein family (related to FCHo1/2)
01

Overview

SH3GL interacting endocytic adaptor 1 (SGIP1) is a brain-expressed endocytic adaptor protein involved in clathrin-mediated endocytosis and energy homeostasis. SGIP1 interacts with multiple endocytic and scaffold proteins (including endophilins, Eps15, AP-2, intersectin), modulating plasma membrane curvature and vesicle formation through its membrane phospholipid-binding domain, proline-rich domain, and C-terminal μ-homology domain. The alternative splicing variant SGIP1α (in mice) is essential for clathrin-mediated endocytosis due to additional regions in its MP domain driving membrane deformation and oligomerization. SGIP1’s role in neuronal signaling, energy regulation, and potential involvement in metabolic and neuropsychiatric disorders—as well as its value as a biomarker for hepatocellular carcinoma—underscore its functional importance, though it is not currently a direct therapeutic target[1][2][3].

Other names
SH3-containing GRB2-like protein 3-interacting protein 1DKFZp761D221Endophilin-3-interacting proteinSH3 domain GRB2 like endophilin interacting protein 1endophilin-3-interacting proteinSGIP1
02

Biological functions

Clathrin-mediated endocytosisMembrane tubulation/deformationEnergy homeostasis regulationReceptor signaling modulation (especially in neuronal systems)Vesicle-mediated transport
03

Disease associations

Obesity and diabetes (SGIP1 expression influences hypothalamic control of food intake and bodyweight)Alcohol dependence and neuropsychiatric traits (genetic variation alters EEG signals associated with psychiatric vulnerability)Hepatocellular carcinoma (SGIP1 methylation as a non-invasive diagnostic/prognostic biomarker)
04

Safety considerations

There are no reported therapeutic compounds targeting SGIP1, so safety concerns from direct intervention are unknown[2][3]. However, its role in neuronal signaling and metabolic control suggests that off-target effects could arise in experimental modulation.
05

Biomarkers

Plasma methylation of SGIP1 is a potential non-invasive biomarker for hepatocellular carcinoma

Beyond the preview

Go deeper on SH3GL interacting endocytic adaptor 1 (SGIP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SH3GL interacting endocytic adaptor 1 (SGIP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call